Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension (Q40547439)

21 September 2017

Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension (English)

1 reference

21 September 2017

Mukerjee D

1

1 reference

21 September 2017

Yap LB

2

1 reference

21 September 2017

Holmes AM

3

1 reference

21 September 2017

Nair D

4

1 reference

21 September 2017

Ayrton P

5

1 reference

21 September 2017

Black CM

6

1 reference

21 September 2017

Coghlan JG

7

1 reference

21 September 2017

1 November 2003

1 reference

21 September 2017

1 reference

21 September 2017

97

1 reference

21 September 2017

1230-1236

1 reference

21 September 2017

11

1 reference

Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy.

21 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

The heart and pulmonary vasculature in scleroderma: clinical features and pathobiology

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Guidelines for the diagnosis and treatment of chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Treatment of pulmonary hypertension secondary to connective tissue diseases.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Plasma concentrations and comparisons of brain natriuretic peptide and atrial natriuretic peptide in normal subjects, cardiac transplant recipients and patients with dialysis-independent or dialysis-dependent chronic renal failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Plasma brain natriuretic peptide as a noninvasive marker for efficacy of pulmonary thromboendarterectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Cardiac fibrosis in mice lacking brain natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Brain natriuretic peptide appears to act locally as an antifibrotic factor in the heart.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Inhibitory regulation of hypertrophy by endogenous atrial natriuretic peptide in cultured cardiac myocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Natriuretic peptide receptors and the heart

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Modulation of endocardial natriuretic peptide receptors in right ventricular hypertrophy

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Nesiritide: a new drug for the treatment of decompensated heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

Utility of B-natriuretic peptide levels in identifying patients with left ventricular systolic or diastolic dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900254-3

7 January 2021

10.1016/S0954-6111(03)00254-3

Identifiers

DOI

1 reference

21 September 2017

1 reference